Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1994 Mar 15;91(6):2334–2338. doi: 10.1073/pnas.91.6.2334

4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

E Buchdunger 1, U Trinks 1, H Mett 1, U Regenass 1, M Müller 1, T Meyer 1, E McGlynn 1, L A Pinna 1, P Traxler 1, N B Lydon 1
PMCID: PMC43365  PMID: 8134396

Abstract

Deregulated signal transduction via the epidermal growth factor receptor (EGF-R) family of protein-tyrosine kinase growth factor receptors is associated with proliferative diseases. We describe a class of compounds (4,5-dianilinophthalimides) that inhibit the EGF-R protein-tyrosine kinase in vitro with high selectivity. In cells, 4,5-dianilinophthalmide selectively inhibited both ligand-induced EGF-R and p185c-erbB2 autophosphorylation and c-fos mRNA induction. Antitumor activity could be demonstrated in vivo against xenografts of the A431 and SK-OV-3 tumors, which overexpress the EGF-R and p185c-erbB2, respectively. In contrast, a platelet-derived growth factor-driven tumor was not inhibited by 4,5-dianilinophthalimide, which is compatible with its cellular selectivity and hypothesized mechanism of action. No overt cumulative toxicity was observed during treatment even though high efficacy was observed, indicating a good therapeutic window. 4,5-Dianilinophthalimides may offer therapeutic agents for the treatment of hyperproliferative diseases that overexpress EGF-R family protein-tyrosine kinases or their ligands.

Full text

PDF
2334

Images in this article

2336Image
on p.2336
2336Image
on p.2336
2337Image
on p.2337
2337Image
on p.2337

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agostinis P., Pinna L. A., Meggio F., Marin O., Goris J., Vandenheede J. R., Merlevede W. A synthetic peptide substrate specific for casein kinase I. FEBS Lett. 1989 Dec 18;259(1):75–78. doi: 10.1016/0014-5793(89)81498-x. [DOI] [PubMed] [Google Scholar]
  2. Andrejauskas-Buchdunger E., Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res. 1992 Oct 1;52(19):5353–5358. [PubMed] [Google Scholar]
  3. Bertics P. J., Chen W. S., Hubler L., Lazar C. S., Rosenfeld M. G., Gill G. N. Alteration of epidermal growth factor receptor activity by mutation of its primary carboxyl-terminal site of tyrosine self-phosphorylation. J Biol Chem. 1988 Mar 15;263(8):3610–3617. [PubMed] [Google Scholar]
  4. Bit R. A., Davis P. D., Elliott L. H., Harris W., Hill C. H., Keech E., Kumar H., Lawton G., Maw A., Nixon J. S. Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. J Med Chem. 1993 Jan 8;36(1):21–29. doi: 10.1021/jm00053a003. [DOI] [PubMed] [Google Scholar]
  5. Brunati A. M., Allee G., Marin O., Donella-Deana A., Cesaro L., Bougeret C., Fagard R., Benarous R., Fischer S., Pinna L. A. Spleen protein tyrosine kinases TPK-IIB and CSK display different immunoreactivity and opposite specificities toward c-src-derived peptides. FEBS Lett. 1992 Nov 30;313(3):291–294. doi: 10.1016/0014-5793(92)81212-5. [DOI] [PubMed] [Google Scholar]
  6. Buss J. E., Kudlow J. E., Lazar C. S., Gill G. N. Altered epidermal growth factor (EGF)-stimulated protein kinase activity in variant A431 cells with altered growth responses to EGF. Proc Natl Acad Sci U S A. 1982 Apr;79(8):2574–2578. doi: 10.1073/pnas.79.8.2574. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem. 1987;56:881–914. doi: 10.1146/annurev.bi.56.070187.004313. [DOI] [PubMed] [Google Scholar]
  8. Chen W. S., Lazar C. S., Poenie M., Tsien R. Y., Gill G. N., Rosenfeld M. G. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. 1987 Aug 27-Sep 2Nature. 328(6133):820–823. doi: 10.1038/328820a0. [DOI] [PubMed] [Google Scholar]
  9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  10. Cola C., Brunati A. M., Borin G., Ruzza P., Calderan A., De Castiglione R., Pinna L. A. Synthetic peptides reproducing the EGF-receptor segment homologous to the pp60v-src phosphoacceptor site. Phosphorylation by tyrosine protein kinases. Biochim Biophys Acta. 1989 Jul 11;1012(2):191–195. doi: 10.1016/0167-4889(89)90095-5. [DOI] [PubMed] [Google Scholar]
  11. Curran T., Peters G., Van Beveren C., Teich N. M., Verma I. M. FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol. 1982 Nov;44(2):674–682. doi: 10.1128/jvi.44.2.674-682.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Davis P. D., Hill C. H., Keech E., Lawton G., Nixon J. S., Sedgwick A. D., Wadsworth J., Westmacott D., Wilkinson S. E. Potent selective inhibitors of protein kinase C. FEBS Lett. 1989 Dec 18;259(1):61–63. doi: 10.1016/0014-5793(89)81494-2. [DOI] [PubMed] [Google Scholar]
  13. Di Fiore P. P., Pierce J. H., Fleming T. P., Hazan R., Ullrich A., King C. R., Schlessinger J., Aaronson S. A. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell. 1987 Dec 24;51(6):1063–1070. doi: 10.1016/0092-8674(87)90592-7. [DOI] [PubMed] [Google Scholar]
  14. Di Fiore P. P., Pierce J. H., Kraus M. H., Segatto O., King C. R., Aaronson S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987 Jul 10;237(4811):178–182. doi: 10.1126/science.2885917. [DOI] [PubMed] [Google Scholar]
  15. Donella-Deana A., Marin O., Brunati A. M., Pinna L. A. Selective effect of poly(lysine) on the enhancement of the lyn tyrosine protein kinase activity. Increased specificity toward src peptides. Eur J Biochem. 1992 Mar 15;204(3):1159–1163. doi: 10.1111/j.1432-1033.1992.tb16742.x. [DOI] [PubMed] [Google Scholar]
  16. Druker B. J., Mamon H. J., Roberts T. M. Oncogenes, growth factors, and signal transduction. N Engl J Med. 1989 Nov 16;321(20):1383–1391. doi: 10.1056/NEJM198911163212007. [DOI] [PubMed] [Google Scholar]
  17. Evans B. D., Smith I. E., Shorthouse A. J., Millar J. L. A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. Br J Cancer. 1982 Mar;45(3):466–468. doi: 10.1038/bjc.1982.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Geissler J. F., Roesel J. L., Meyer T., Trinks U. P., Traxler P., Lydon N. B. Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase. Cancer Res. 1992 Aug 15;52(16):4492–4498. [PubMed] [Google Scholar]
  19. Geissler J. F., Traxler P., Regenass U., Murray B. J., Roesel J. L., Meyer T., McGlynn E., Storni A., Lydon N. B. Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors. J Biol Chem. 1990 Dec 25;265(36):22255–22261. [PubMed] [Google Scholar]
  20. Giard D. J., Aaronson S. A., Todaro G. J., Arnstein P., Kersey J. H., Dosik H., Parks W. P. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973 Nov;51(5):1417–1423. doi: 10.1093/jnci/51.5.1417. [DOI] [PubMed] [Google Scholar]
  21. Gullick W. J., Berger M. S., Bennett P. L., Rothbard J. B., Waterfield M. D. Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer. 1987 Aug 15;40(2):246–254. doi: 10.1002/ijc.2910400221. [DOI] [PubMed] [Google Scholar]
  22. Gullick W. J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull. 1991 Jan;47(1):87–98. doi: 10.1093/oxfordjournals.bmb.a072464. [DOI] [PubMed] [Google Scholar]
  23. Halter S. A., Dempsey P., Matsui Y., Stokes M. K., Graves-Deal R., Hogan B. L., Coffey R. J. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations. Am J Pathol. 1992 May;140(5):1131–1146. [PMC free article] [PubMed] [Google Scholar]
  24. Harwerth I. M., Wels W., Marte B. M., Hynes N. E. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem. 1992 Jul 25;267(21):15160–15167. [PubMed] [Google Scholar]
  25. Honegger A. M., Dull T. J., Felder S., Van Obberghen E., Bellot F., Szapary D., Schmidt A., Ullrich A., Schlessinger J. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell. 1987 Oct 23;51(2):199–209. doi: 10.1016/0092-8674(87)90147-4. [DOI] [PubMed] [Google Scholar]
  26. Hynes N. E. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol. 1993 Feb;4(1):19–26. [PubMed] [Google Scholar]
  27. Hynes N. E., Gerber H. A., Saurer S., Groner B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J Cell Biochem. 1989 Feb;39(2):167–173. doi: 10.1002/jcb.240390208. [DOI] [PubMed] [Google Scholar]
  28. McGlynn E., Becker M., Mett H., Reutener S., Cozens R., Lydon N. B. Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors. Eur J Biochem. 1992 Jul 1;207(1):265–275. doi: 10.1111/j.1432-1033.1992.tb17047.x. [DOI] [PubMed] [Google Scholar]
  29. McGlynn E., Liebetanz J., Reutener S., Wood J., Lydon N. B., Hofstetter H., Vanek M., Meyer T., Fabbro D. Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus. J Cell Biochem. 1992 Jul;49(3):239–250. doi: 10.1002/jcb.240490306. [DOI] [PubMed] [Google Scholar]
  30. Meggio F., Perich J. W., Johns R. B., Pinna L. A. Partially dephosphorylated phosphopeptide AcSer(P)-Ser(P)-Ser(P) is an excellent substrate for casein kinase-2. FEBS Lett. 1988 Sep 12;237(1-2):225–228. doi: 10.1016/0014-5793(88)80206-0. [DOI] [PubMed] [Google Scholar]
  31. Meyer T., Regenass U., Fabbro D., Alteri E., Rösel J., Müller M., Caravatti G., Matter A. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer. 1989 May 15;43(5):851–856. doi: 10.1002/ijc.2910430519. [DOI] [PubMed] [Google Scholar]
  32. Sandgren E. P., Luetteke N. C., Palmiter R. D., Brinster R. L., Lee D. C. Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell. 1990 Jun 15;61(6):1121–1135. doi: 10.1016/0092-8674(90)90075-p. [DOI] [PubMed] [Google Scholar]
  33. Santon J. B., Cronin M. T., MacLeod C. L., Mendelsohn J., Masui H., Gill G. N. Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice. Cancer Res. 1986 Sep;46(9):4701–4705. [PubMed] [Google Scholar]
  34. Schlessinger J., Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron. 1992 Sep;9(3):383–391. doi: 10.1016/0896-6273(92)90177-f. [DOI] [PubMed] [Google Scholar]
  35. Sonobe M. H., Bravo R., Armelin M. S. Imbalanced expression of cellular nuclear oncogenes caused by v-sis/PDGF-2. Oncogene. 1991 Sep;6(9):1531–1537. [PubMed] [Google Scholar]
  36. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991 Aug 25;266(24):15771–15781. [PubMed] [Google Scholar]
  37. Vassar R., Hutton M. E., Fuchs E. Transgenic overexpression of transforming growth factor alpha bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis. Mol Cell Biol. 1992 Oct;12(10):4643–4653. doi: 10.1128/mcb.12.10.4643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Velu T. J., Beguinot L., Vass W. C., Willingham M. C., Merlino G. T., Pastan I., Lowy D. R. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science. 1987 Dec 4;238(4832):1408–1410. doi: 10.1126/science.3500513. [DOI] [PubMed] [Google Scholar]
  39. Wels W., Harwerth I. M., Mueller M., Groner B., Hynes N. E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 1992 Nov 15;52(22):6310–6317. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES